Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th

Bicara Therapeutics’ (NASDAQ:BCAX) lock-up period is set to expire on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. After the expiration of Bicara Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BCAX shares. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. HC Wainwright raised their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $16.55 on Friday. The firm has a fifty day simple moving average of $13.53. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Institutional Trading of Bicara Therapeutics

Several large investors have recently bought and sold shares of BCAX. Vestal Point Capital LP boosted its stake in shares of Bicara Therapeutics by 67.1% during the fourth quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock valued at $12,368,000 after purchasing an additional 285,000 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $348,000. Red Tree Management LLC purchased a new position in Bicara Therapeutics in the fourth quarter worth $55,230,000. Nuveen Asset Management LLC purchased a new position in Bicara Therapeutics in the fourth quarter worth $436,000. Finally, Orbimed Advisors LLC raised its stake in shares of Bicara Therapeutics by 9.7% in the fourth quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after buying an additional 26,391 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.